HLB LifeScience
Difference Made Together

  • HLB LifeScience Bio Business

    • Tegatrabeten (BC-2059)
      Tegatrabeten (BC-2059) is a new chemotherapeutic agent that blocks the Wnt / beta-catenin signaling pathway in cancer stem cells. It has few side effects and is independent of the mutation of beta-catenin. So it is an effective anti-cancer clinical drug for various cancers.
    • SP-2577
      SP-2577 is highly bioavailable, irreversible and highly selective Lysine Specific Demethylase 1 (LSD1) inhibitor is used for various cancers. (prostate cancer, breast cancer, Small cell lung cancer, bladder cancer,
      neuroblastoma, etc.)
    • Core Technology
      Driving innovation across oncology,
      immunology, neuroscience and more.
    • Pipeline
      Advancing medicines with strong clinical
      performance in areas of great need.
    • Research Achievement
      Work with us to turn world-class research
      into life-changing results.